Share. Connect. Create. Grow. · Socialiya
Analysts ‘shaking heads’ after Regeneron melanoma drug fails to beat Keytruda in phase 3 trial

The phase 3 study of the LAG-3 inhibitor missed its primary endpoint, leaving Regeneron reeling from...

BUSINESS NEWS May 18, 2026

Analysts ‘shaking heads’ after Regeneron melanoma drug fails to beat Keytruda in phase 3 trial

The phase 3 study of the LAG-3 inhibitor missed its primary endpoint, leaving Regeneron reeling from the second failure of a key late-stage program.

9 views 0 likes 0 comments
Share:
The phase 3 study of the LAG-3 inhibitor missed its primary endpoint, leaving Regeneron reeling from the second failure of a key late-stage program.

Author: Fierce Biotech

Read Original Article

Related News

Advertisement
socialiya
Advertisement

Top Categories

Advertisement
socialiya
Advertisement
socialiya
Advertisement
socialiya
Advertisement
socialiya